INTRODUCTION
Atherosclerosis manifests as lesions within the walls of largeto medium-sized arteries. The development of these lesions involves a complex interplay of factors and cell types, including endothelial, smooth muscle and immune cells. Within the vasculature, and within the medial smooth muscle layer specifically, many vascular GFs (growth factors) play a role in exacerbating atherogenesis, although the details of their respective signalling networks remain to be fully characterized. The ability of these GFs to activate SMCs (smooth muscle cells) contributes to the synthetic, migrative and proliferative responses that eventually lead to their accumulation in the subendothelial space and ultimately to progressive vessel occlusion [1] . IGF-1 (insulin-like GF 1), in particular, is closely related to insulin and has often been examined for its involvement in metabolism. However, it remains an important GF with significant involvement in the SMC switch from a functional contractile phenotype to an activated synthetic phenotype.
IGF-1 operates by activating an α 2 β 2 heterotetrameric tyrosine kinase receptor, which undergoes autophosphorylation and initiates a distinct number of signalling events [2] . These include the PI3K (phosphatidylinositol 3-kinase)-Akt cascade, which leads to cell cycle progression and cell proliferation, and the ERK1/2 (extracellular-signal-regulated kinase 1/2)-p21 Ras cascade, which is also essential to the mitogenic actions of IGF-1 (reviewed in [3] ).
We and others have previously shown in a variety of cell types that IGF-1-induced ERK1/2 activation does not require active tyrosine kinase signalling [4, 5] . In the past, it has been suggested that an alternative signalling component, specifically one involving a G-protein, may be linked to IGF-1R (IGF-1 receptor) induced ERK1/2 activation. This hypothesis was a reflection of a number of studies that showed that some of the IGF-1R's cellular effects could be inhibited by either PTX (pertussis toxin) [6] [7] [8] or by β-ARK-CT (β-adrenergic receptor kinase C-terminus) [9] , inhibitors of G αi -sensitive and G βγ signalling respectively. Of particular relevance, the study by Luttrel et al. [9] was the first to link G βγ signalling to ERK1/2 activation. Although this was originally thought to involve transactivation of a GPCR (G-protein-coupled receptor), it was later shown that the IGF-1R co-precipitates with the separate subunits of a G-protein [10, 11] , which suggests that G-protein activation is probably independent of GPCRs. However, it remains unclear whether the G α -subunit is directly involved in signalling, as different studies have reported conflicting results [11, 12] . Correspondingly, we recently suggested that a functional G βγ -subunit is required for IGF-1R signalling in VSMCs (vascular SMCs) [13] . In the present study, we examine G-protein coupling to the IGF-1R in depth, and establish which signalling events are initiated by activation of the individual subunits. Furthermore, we investigate the roles played by the individual subunits of the G-protein on the processes that involve SMCs in the pathogenesis of atherosclerosis.
Primary SMC cultures were established as described previously [14] from the left anterior descending coronary arteries of fresh porcine hearts. Only passages 3-5 were used to maintain consistency between cultures. Quiescence was induced by transferring cells at 80 % confluency into serum-free medium consisting of DMEM (Dulbecco's modified Eagle's medium) supplemented with PTSA (0.1 mM pyruvate, 5 μg/ml transferrin, 1 nM selenium and 200 μM ascorbate).
Western blotting
Western blotting analysis of total protein extracts prepared by direct addition of 2× SDS/PAGE loading buffer was done as described previously [4] . Protein was loaded on to either 10 % or 7.5 % polyacrylamide gels and transferred on to PVDF membranes prior to blotting with antibodies from Cell Signaling Technology [antibodies specific to phospho-Akt, Akt, phospho-CREB (cAMP-response-element-binding protein), CREB, G α (pan), IGF-1Rβ, phospho-ERK1/2, ERK1/2 and β-tubulin], Abcam (G αs and G β ) or NewEast Biosciences (G αi ).
IP (immunoprecipitation)
IP of 250 μg of total cell lysates was performed as described previously [15] . All Western blotting of immunoprecipitated samples was done using an overnight incubation with primary antibody. All antibodies were used at a dilution of 1:75 for precipitation unless otherwise noted, and were from Cell Signaling Technology [anti-Gα (pan) and anti-IGF-1Rβ], Abcam (anti-His 6 ) or NewEast Biosciences (anti-GTP-G αi and anti-GTP-G αs ). Control IgG was either from Jackson ImmunoResearch or was an unrelated primary antibody from Cell Signaling Technology. Clean Blot IP Detection Reagent HRP (horseradish peroxidase) (Thermoscientific) served as a secondary antibody.
In vitro GST (glutathione transferase) IP
The methods for GST IP were based on the instruction manual from the ProFound Pull-Down GST Protein:Protein Interaction Kit (Pierce). Recombinant GST (1 μg)-tagged G α bait protein (Abnova) was used to capture 1 μg of recombinant prey IGF-1R (Abcam), which was subsequently released with wash solution containing 100 mM glutathione.
To analyse IGF-1 binding, equal amounts of each eluted sample were combined 1:1 with 2× sample buffer and 0.05 M NaOH and analysed using immunoblotting. To display precipitated GST-G α proteins, the remaining eluate was concentrated using a Centrifugal Filter Device (Millipore). Samples were first added directly into the filter device, placed inside a filtrate collection tube and centrifuged for 15 min at 15 000 g, 4
• C. The concentrate was then combined 1:1 with 2× sample buffer and the proteins were separated by SDS/PAGE. The gel was then stained for 90 min with Oriole fluorescent stain (Bio-Rad Laboratories).
Competition assay
Recombinant IGF-1R (1 μg) was combined in 200 μl IP buffer (0.5 mM MgCl 2 , 68.2 mM NaCl, 10 mM Tris/HCl, pH 7.4, 5 % glycerol and 0.5 % Nonidet P40) with 2 μg each of recombinant GST-G αi1 and GST-G αi2 and rotated at 4
• C for 1 h. Primary anti-(His 6 ) antibody was added at a dilution of 1:200 and IP was performed as described above. Samples were run on SDS/PAGE (10 % gel) alongside 1 μg of non-assayed GST-G αi1 and GST-G αi2 . The gel was subsequently stained for 90 min in the dark using Oriole fluorescent stain.
Protein-protein interaction binding assay
Recombinant proteins were combined at appropriate concentrations in sodium phosphate sample buffer (0.1 M NaH 2 PO 4 , 0.1 M Na 2 HPO 4 and 20 % glycerol) and mixed at 4
• C for 45 min. Bromophenol Blue (10 %) was added to each sample at a 1:10 ratio. Native 7.5 % polyacrylamide gels were prepared using the Mops-histidine pH 6.6 gel system [16] and His-Mops running buffer (consisting of 25 mM histidine and 30 mM Mops). Following a 2 h gel pre-run at 300 V, samples were loaded on to the gel and after electrophoresis were transferred on to PVDF membranes. Membranes were blotted for IGF-1R and non-linear curve fitting of the band intensities was used to calculate K d and B max with GraphPad Prism 5 software.
BrdU (bromodeoxyuridine) cell proliferation assay
Assay methods were based on the datasheet for the BrdU Cell Proliferation Assay (Chemicon). Cells were seeded at 1×10 5 cells/well in 100 μl of growth medium consisting of 20 % FBS (fetal bovine serum), DMEM plus 1×antibiotic/antimycotic. They were left to attach and proliferate for 48 h before being placed into PTSA-supplemented medium for 3 days. Test reagents were then diluted at twice the final desired concentration in the same medium, and 100 μl was added directly to each well. The plate was incubated another 24 h at 37
• C before adding 20 μl/well of 1×BrdU reagent, diluted in DMEM plus PTSA. The plate was left to incubate for 24 h at 37
• C. Proliferation was quantified by measuring absorbance with a microplate reader, read at the dual wavelengths of 450 and 540 nM.
Cell migration assay
Cell migration was assessed as passage through 8.0 μm pores of the PET (polyethylene terephthalate) membrane of a 24-well culture plate insert (Falcon). Cells (5×10 4 ) were seeded on to the PET membranes in growth medium. They were left to attach and proliferate for 48 h, then placed into PTSA-supplemented medium for 4 days. Test reagents were diluted to the final desired concentration in DMEM plus PTSA and added to the wells of the companion feeder plates. Cells were left to incubate at 37
• C for 72 h to allow cell migration through the porous membrane.
Cells on the inside of the insert membrane were scraped off with a rubber policeman. The cells on the underside of the membrane were fixed for 5 min in a 4 % PFA (paraformaldehyde) solution (consisting of 1.75 mM NaOH, 0.9 % NaCl, 4 % PFA and 0.15 M Na 3 PO 4 ). Membranes were washed with PBS (consisting of 0.1 M Na 3 PO 4 and 0.9 % NaCl) three times for 10 min. Hoechst 33258 (Sigma) at 5 μg/ml, diluted in PBS, was applied to the cells for 2 min. This was followed by three rounds of washing for 10 min. The membranes were removed from the inserts and mounted on to microscope slides using Aqua-Mount Aqueous Mountant (Lerner Laboratories). Migration was quantified by counting the number of fluorescing cells at 460 nm in three separate representative fields.
Cell lysate preparation for phospho-screen
The protocol was based on the Antibody Microarray Analysis Customer Information Package from Kinexus. Following treatment, cells were rinsed with ice-cold PBS and scraped with 200 μl of Kinexus Buffer at pH 7.2 (consisting of 20 mM Mops, 2 mM EGTA, 5 mM EDTA and 1 % Triton X-100) containing freshly added 1× Halt protease inhibitor cocktail, 1× Halt phosphatase inhibitor cocktail (both from Thermoscientific) and 1 mM dithiothreitol. Lysates were then sonicated four times for 10 s, with 10 s intervals on ice, followed by ultracentrifugation at 44 000 rev./min for 30 min (Rotor MLA130, Beckman Coulter Optima MAX Ultracentrifuge). The supernatant was transferred to a fresh screw cap vial and sent to Kinexus Bioinformatics (Vancouver, BC, Canada) for KAM-1.2PN phospho-antibody microarray screening.
Data analysis
Data are graphically represented as means + − S.E.M. All experiments were replicated at least three times. Treatment means were compared using one-way ANOVA and significance was assumed where P < 0.05.
RESULTS

IGF-1-induced SMC migration and proliferation are attenuated by G βγ inhibition
Co-precipitation of G-proteins with the IGF-1R has not been examined in VSMCs. IP revealed that G β associates with the β-subunit of the IGF-1R in an activation-dependent manner, with IGF-1 stimulation decreasing co-precipitation of G β ( Figure 1A ). Control IPs (lacking primary antibody; results not shown) and using whole serum rabbit IgG ( Figure 1A ) did not precipitate the identified protein.
As it has been shown that inhibitors of G βγ prevent IGF-1-induced ERK1/2 activation [9,13], but not PDGF (plateletderived GF) activation (results not shown), we examined whether G βγ inhibition affected the proliferation and migration of SMCs. Proliferation was examined using a BrdU incorporation assay. As shown in Figure 1 (B), cells in the untreated control group exhibited low levels of background staining. Staining intensity was significantly increased by both IGF-1 and PDGF-BB, the latter serving as a positive control. Both the G βγ inhibitor gallein [17] and the IGF-1R tyrosine kinase inhibitor tyrphostin AG1024 [18] significantly inhibited IGF-1-induced proliferation. Gallein returned the levels to those observed in the untreated cells, whereas AG1024 even inhibited background proliferation. On the basis of the results of a previous study [12] , the PI3K inhibitor LY294002 [19] was also used to investigate the implication of this pathway in proliferation. Consistent with the effects of IGF-1R kinase inhibition, inhibition of the PI3K pathway abrogated proliferation.
Next, we examined the contribution of G βγ to IGF-1-induced migration through the pores of a PET membrane. Figure 1 (C) shows the data obtained by the quantification of the number of cells visible in three microscope fields per treatment relative to the control. These results demonstrate that both gallein and AG1024 are able to completely block IGF-1-induced migratory activity.
The IGF-1R co-precipitates G α and specifically activates G αi
To verify that the IGF-1R also interacts with the G α -subunit of the G-protein, we immunoprecipitated each component separately. Figure 2 (A) shows reciprocal co-precipitation of the IGF-1Rβ and G α . Control IPs (lacking primary antibody and using whole serum rabbit IgGs) did not precipitate the identified protein (results not shown). Interestingly, this association was not affected by the presence of either IGF-1 alone or of IGF-1 plus AG1024. The Table 1 Binding parameters for the interaction of different G α subunits with the cytoplasmic subunit of the IGF-1R as determined by saturation binding analysis Recombinant peptides of various concentrations were mixed in a non-denaturing buffer for 45 min and subsequently run on a native gel of pH 6.6. Binding intensity was quantified by scanning densitometry. The data were analysed by non-linear regression using GraphPad Prism 5. [7, 20] , none have yet shown direct activation of G αi following IGF-1R stimulation. Using a method involving configuration-specific GTP-bound G α -subunits [21] , we demonstrate that IGF-1 does indeed cause activation of G αi ( Figure 2B ). Using the same method, we also demonstrate that this activation is G αi -specific, as G αs was not activated. GTP [S] (guanosine 5 -[γ -thio]triphosphate)-induced controls show a 4.81-and 2.08-fold increase over GDP control levels in the G αi and G αs experiments respectively ( Figure 2B ). As IGF-1R activation is typically associated with receptor autophosphorylation, we examined whether activation of G αi is dependent on the activity of the tyrosine kinase. Addition of AG1024 before IGF-1 stimulation did not prevent the activation of G αi ( Figure 2C ). Controls show a 6.35-fold GTP[S]-induced activation over GDP levels. These results indicate that G αi is selectively activated by the IGF-1R using a mechanism independent of the intrinsic receptor tyrosine kinase.
The IGF-1R can directly interact with both G αi1 and G αi2
To determine whether the IGF-1R and G αi interact directly or indirectly through a protein complex, we examined binding in vitro, in the absence of potential cellular effectors. Since it was shown that G αi is specifically activated by IGF-1, we examined the interaction of different recombinant isoforms of G αi with the recombinant IGF-1R β-subunit. This fragment of the IGF-1R is active and may elicit a biological response in vivo. However, this binding experiment was performed in the absence of ATP and therefore the IGF-1R was not phosphorylated. G αs was included as a negative control. G αi1 and G αi2 , which are endogenously detectable in SMCs [22] , both co-precipitated with IGF-1R. G αi2 and G αi1 were both precipitated to a similar degree by the IGF-1R ( Figure 3A) . The degree of background binding is shown with G αs . Using a native-PAGE protein-protein interaction assay, binding curves were used to determine K d and the B max for the association of IGF-1R with all three G α subunits ( To determine whether binding of G αi to the IGF-1R is affected by the presence of a competing isoform, we performed a competition experiment using limiting amounts of IGF-1R. The slight difference in the size of the two proteins allows us to discriminate between them. As seen in Figure 3(B) , when IGF-1R binding was saturated by GST-G αi peptides, binding of G αi2 is almost completely blocked by G αi1 . 
TAT (trans-activating transcriptional activator)-conjugated peptides can penetrate SMCs and inhibit the actions of G α
To study G αi actions in SMCs downstream of the IGF-1R, selective inhibitor peptides were designed for G αs and G αi . To overcome the low transfection efficiency of our SMC model, the synthesized peptides included the HIV non-toxic [24] TAT domain [25] and a C-terminal sequence derived from G-proteininhibiting peptides identified by Gilchrist et al. [26] . The specific sequences were: Gα s , RRRQRRKKKRDIIQRMHLRQYELLC; and G αi1/2 , RRRQRRKKRTDVIIKNNLKDCGLFC. A 5 -FAM (6-carboxyfluorescein) tag was added to the N-terminal of each peptide for tracking within the cells.
Since functional inhibition of the C-terminal sequence has previously been demonstrated [26] , we sought to verify that the TAT sequence was effectively allowing the inhibitor peptide to enter the cells, using the fluorescence of the 5 -FAM tag to visualize this process. As shown in Figure 4(A) , the peptides appear to accumulate within the cells when added to the culture. Next, to verify inhibitory specificity between G-proteins, quiescent SMCs were incubated with both the control and test inhibitor peptides at increasing concentrations prior to noradrenaline stimulation. The amount of TAT-conjugated peptide added to the cells was based on various studies showing efficient non-toxic cell penetration at concentrations between 5 and 20 μg/ml [27, 28] . A 1 h pre-incubation with the inhibitor peptides was sufficient to completely attenuate noradrenalineinduced activation of CREB at all of the tested concentrations with the control G αs , but not the test G αi , peptide ( Figure 4B ). The extent of inhibition of noradrenaline-and forskolin-induced CREB activation was quantified and the results are shown in Figure 4 (C). The data confirm the specificity of the inhibitor peptides as only G αs inhibited CREB activation. Finally, we also established that incubation with these peptides did not affect the viability of the cells over the indicated incubation period (results not shown).
G αi inhibition does not affect IGF-1-induced SMC proliferation or migration
To determine whether inhibition of G αi affects SMC proliferation and migration, we repeated the BrdU and migration assays in the presence of the inhibitor peptide. Co-incubation of the inhibitor peptide with IGF-1 did not significantly alter the rate of SMC proliferation ( Figure 5A ). Likewise, there was no measurable effect of G αi inhibition on cell migration ( Figure 5B ). As expected, the G αs peptide did not affect either SMC proliferation or migration (results not shown). Given the well-known role of Akt downstream of the IGF-1R RTK (receptor tyrosine kinase) [29] [30] [31] , we tested whether the inhibitor peptide could block the activation of this pathway. Figure 5 (C) shows that the peptide did not prevent Akt activation. However, as expected, kinase inhibition with AG1024 did block Akt activation.
G αi mediates the activation of specific downstream effectors of the IGF-1R
Since the contribution of the G αi component in transducing signals downstream of the IGF-1R has not been clarified [11, 12] , a phospho-protein screen was used to compare an SMC sample stimulated with IGF-1 with an SMC sample pre-incubated with TAT-G αi C-terminal inhibitor peptide before IGF-1 treatment. This allowed us to survey the effect of these treatments on the phosphorylation of approximately 280 sites on over 150 distinct proteins. The significant changes elicited by G αi inhibition that were detected with the phospho-screen are depicted in Table 2 
DISCUSSION
In the present study, we elaborate on previous observations suggesting a role for G-proteins in IGF-1R signalling. We established that the separate G-protein subunits interact with IGF-1R. Furthermore, we show that G βγ -mediated effects are critical for IGF-1R signalling in SMCs, and contribute to both migration and proliferation. G αi is specifically activated with IGF-1 stimulation, and both G αi1 and G αi2 can directly interact with the β-subunit of the receptor. Inhibition with TAT-conjugated peptides blocked the cellular actions of G αi and concurrently affected the downstream phosphorylation of a number of protein targets, including eIF4E, PP1-α and EGFR. However, G αi was not required for either cell proliferation or migration. The accepted series of events that accompany ligand binding to a RTK are initiated by receptor auto-phosphorylation, and subsequent phosphorylation of distinct protein substrates, which are able to interact with phospho-tyrosines of the activated RTKs. Adaptor proteins that contain SH2 (Src homology 2) or PTB (phosphotyrosine-binding) domains couple the receptor to its signalling pathway while having no intrinsic signalling activity. Subsequent activation of the small G-protein Ras occurs through the GEF (guanine-nucleotide-exchange factor) activity of Sos-1 and eventually leads to activation of ERK1/2 [32] . Alternatively, GPCRs directly function as GEFs to promote GTP exchange of their respective G α component. This releases both G α and G βγ to activate their effector enzymes for the creation of various second messengers [33] . All G α classes and G βγ dimers have well-established cellular targets. Specifically, G αi targets adenylyl cyclase and opposes the actions of G αs , whereas G βγ has been linked to the activation of mitogen-activated protein kinases, including ERK1/2, JNK (c-Jun N-terminal kinase) and p38 [13, [34] [35] [36] . Despite the recognized importance of traditional G-protein signalling, the past few years have seen an increase in evidence indicating exceptions to this classical model. The concept that G-proteins are coupled to, and can be activated by, non-traditional and often single transmembrane receptors such as the IGF-1R, was first suggested in the 1980s [6] . Although it has thus far remained underappreciated, it is becoming increasingly accepted in the cellular signalling community [37, 38] . With respect to the IGF-1R, there are a variety of studies reporting that RTK inhibition decreases ERK1/2 activation [39, 40] . However, we have shown that this is not the case in SMCs [13] , and that an alternate pathway must exist that involves G βγ . Other groups have suggested the presence of a G-protein and have shown that the single-transmembrane spanning IGF-1R co-precipitates with the G βγ subunits [10, 11] . This would imply that a GEF mechanism must be in place within the IGF-1R as GEF activity is necessary for G-protein activation. Unfortunately, these studies did not fully clarify whether this G-protein pathway transactivates another receptor, or whether the action is directly downstream.
The results of the present study support those of Dalle et al. [11] and Hallak et al. [10] which suggest that G α uncoupling may not occur upon IGF-1 stimulation whereas, paradoxically, a significant decrease in co-precipitation of G β is observed. This raises interesting questions, as the G βγ -subunits are thought to interact only with their corresponding G α -subunits and not with the receptor. Thus, for G βγ to be released and signal independently of G α , a mechanism for transducing the signal from the receptor directly to G βγ must be in place. The study by Garcia-Hoz et al. [41] proposed a potential solution, suggesting a scaffolding role for G αq .
In relation to ERK1/2, it has been shown that the actions of PTX are not only cell-type dependent, but also that many are still unknown and non-specific [10] . To avoid this issue, we directly identified which G αi is activated upon IGF-1 stimulation regardless of RTK inhibition. This is the first report combining kinase inhibition with IGF-1-induced G αi activation. At this time, it has not been determined what residues within the cytoplasmic domain of the IGF-1R are potentially responsible for interaction with, and activation of, G αi . However, it has been shown that truncation of the C-terminal domain of the IGF-1R abolishes ERK1/2 phosphorylation with minimal effects on autophosphorylation [42] , thereby providing a direction for further investigation.
Although it now appears clear that IGF-1R signalling does overlap with that of G-proteins, past experiments have shown that even co-precipitation does not clearly indicate interaction [43] . In fact, it has even recently been argued that there is still a lack of data showing direct interaction of G-proteins and RTKs, and that this is a "very serious handicap" in this area of research [44] . We addressed this deficiency by examining direct interaction in vitro, in the absence of any potential intermediates that could be involved in complex formation. We found that binding was not specific to one G αi isoform, and that the presence of more than one affects binding of the other. The only other study examining G αi isoforms in connection with the IGF-1R was that of Kuemmerle and Murthy [12] , who indirectly showed activation of G αi2 by IGF-1. Receptor binding to more than one G α is not uncommon (reviewed in [45] ), even within the different isoforms of a certain class. The K d values calculated for G-protein binding to the IGF-1R show that G αi1 has a higher affinity for the receptor than G αi2 , which has a K d value that is closer to that of the control G αs . Thus the receptor is more likely to be bound to G αi1 in the cells. However, the B max of both G αi1 and G αi2 , which represents the saturation point for binding, are similar and are much higher than that of G αs . Accordingly, under saturating conditions such as those present during the in vitro IP experiment, the precipitated amounts of G αi1 and G αi2 appear similar despite the difference in their K d values. The relationship between these two variables is demonstrated with the binding potential, which corresponds to B max /K d . This value represents the capacity for ligand-binding site interaction [23] . The binding potential values, along with the results of our competition assay, are consistent with a model in which the IGF-1R would preferentially bind to G αi1 at rest, but could also bind G αi2 following IGF-1 stimulation and G αi1 release. In addition, this model may explain the constitutive presence of G αi on the IGF-1R even following IGF-1 stimulation.
The TAT-conjugated inhibitor peptides employed in the present study have proven to be very useful tools for studying G-protein actions. Of particular importance is their specificity, which can be expanded to all G α classes. Furthermore, they are applicable to a large group of otherwise non-transfectable cells for which inhibitor peptides are of limited use. Finally, as they appear to be non-toxic in the micromolar range, this makes them a viable option for applications beyond in vitro experiments.
Two major contributions of SMCs with respect to atherogenesis and restenosis lie in their proliferative and migratory responses. In their study, Kuemmerle and Murthy [12] suggested that two distinct and additive growth pathways are initiated upon IGF-1R activation: one would be ERK1/2-dependent, initiated by a Gprotein, whereas the other would be PI3K-dependent, initiated by the RTK. They arrived at this conclusion by targeting G αi with PTX. In the present study, BrdU incorporation was measured in SMCs under various conditions, including inhibition of the RTK, PI3K, G βγ and G αi . We show that G βγ inhibition is able to attenuate proliferation to a similar degree as RTK and PI3K inhibition, but that G αi inhibition had no effect. Conversely, Akt, which is a protein activated downstream of PI3K, was also unaffected by G αi inhibition. This suggests that, at least in vascular SMCs, the two distinct pathways suggested by Kuemmerle and Murthy [12] , namely the ERK1/2-and PI3K/Akt-dependent pathways, are likely to be independent of each other.
There have been no reports thus far of a connection between cell migration and this novel pathway. Our results suggest a role for IGF-1-G βγ , but not IGF-1-G αi . This further supports the presence of two parallel pathways activated by IGF-1, but neither is dependent upon G αi activation. The relevance of these findings is highlighted in a study by Iaccarino et al. [46] , who investigated the role of G βγ signalling in revascularization and provided evidence that G βγ targeting holds significant potential in the attenuation of restenosis.
Whether G α signals downstream of the IGF-1R is a question which has thus far remained unresolved, as some studies have suggested no change in G α coupling [10, 11] , whereas one suggested a role in inhibiting adenylyl cyclase leading to cell growth [12] . Of note, however, is that the latter study, which was the only one suggesting a role for G α , was also the only one performed in non-rodent primary cells. This, combined with the observation that more than one G α can bind to the receptor, suggests that G α signalling may indeed be active downstream of the IGF-1R in porcine VSMCs, despite no observed change in coupling.
A microarray-based phospho-screen was an ideal method to screen possible implications of G αi signalling. In addition to identifying likely downstream targets, this approach also confirmed that the inhibitor peptide is indeed functional in our model, a fact that could not be realistically assessed in the absence of known targets. Among the proteins whose phosphorylation was shown to be significantly affected by G αi inhibition are ErbB2, eIF4E, the PP1-α catalytic subunit, EGFR and several histones. The involvement of IGF-1 in protein synthesis and translation is a documented concept [47] , as is the involvement of eIF4E [48, 49] . However, this phenomenon has thus far been attributed to mTOR (mammalian target of rapamycin) and not to G αi . Whether G αi is involved in a separate but complementary pathway is a question which cannot yet be answered. In contrast with its effects on eIF4E, G αi appears to inhibit the phosphorylation of PP1-α, thereby activating this phosphatase. Finally, there appears to be significant involvement of the EGFR family (EGFR and ErbB2) downstream of G αi , which could contribute to the mechanism by which the IGF-1R axis interacts with the mitogenic responses initiated by EGF [50] . This suggests receptor cross-talk on a different level, an observation that can also be applicable in the cancer field.
IGF-1-induced G αi signalling also targets histone phosphorylation. Potential targets cannot be discerned with the current information as IGF-1 stimulation was acute. However, a role for histone phosphorylation, and particularly H3 on Thr 11 , has been identified in mitosis [51] . Figure 6 presents a possible model to summarize the results obtained in the present study. Our results show that the IGF-1R in SMCs can operate via a signalling pathway which is independent of the RTK and involves a G-protein. Furthermore, both the G βγ and G α components have downstream signalling targets, and G βγ specifically is involved in the cellular processes leading to vascular pathologies.
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